Table 2. Causal effects, sensitivity and pleiotropy test between 2-methylbutyroylcarnitine with cancers.
| Cancer type | IVW | MR-Egger | Weighted median | MR-PRESSO | MR-Egger regression | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | Egger intercept | Pleiotropy test | ||||
| Breast cancer | 0.77 (0.70–0.85) | 3.42E-07 | 1.59 (1.27–1.99) | 6.23E-05 | 1.01 (0.91–1.11) | 9.35E-01 | 0.682 | −0.0045 | 0.0458 | ||
| ER+ breast cancer | 0.72 (0.64–0.80) | 3.55E-09 | 1.58 (1.23–2.02) | 3.06E-04 | 1.00 (0.90–1.12) | 9.45E-01 | 0.792 | −0.0038 | 0.1506 | ||
| Glioma | 2.19 (1.17–4.09) | 0.015 | 0.89 (0.16–4.96) | 8.95E-01 | 1.99 (0.75–5.31) | 1.67E-01 | 0.216 | −0.0054 | 0.8026 | ||
| Lung cancer | 0.59 (0.50–0.70) | 1.98E-09 | 1.60 (1.08–2.36) | 1.91E-01 | 0.85 (0.66–1.09) | 2.03E-01 | <0.001 | −0.0025 | 0.6381 | ||
| Lung adenocarcinoma | 0.60 (0.48–0.75) | 1.14E-05 | 1.72 (1.005–2.96) | 4.82E-02 | 0.59 (0.41–0.87) | 7.20E-03 | 0.123 | −0.0002 | 0.9826 | ||
| Squamous cell lung cancer | 0.78 (0.63–0.98) | 3.3E-02 | 1.97 (1.17–3.32) | 1.12E-02 | 1.28 (0.89–1.84) | 1.79E-01 | 0.452 | −0.0079 | 0.3344 | ||
| Ovarian cancer | 0.77 (0.68–0.86) | 3.00E-06 | 1.17 (0.90–1.53) | 2.45E-01 | 0.63 (0.52–0.75) | 4.77E-07 | 0.319 | −0.0040 | 0.3235 | ||
ER, estrogen receptor; IVW, inverse variance weighted; MR, Mendelian randomization.